nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—PHKG2—hindbrain—obesity	0.0113	0.0561	CbGeAlD
Afatinib—ERBB2—gall bladder—obesity	0.01	0.0498	CbGeAlD
Afatinib—DYRK1A—hindbrain—obesity	0.00979	0.0486	CbGeAlD
Afatinib—ERBB2—respiratory system—obesity	0.00621	0.0308	CbGeAlD
Afatinib—ERBB4—respiratory system—obesity	0.00621	0.0308	CbGeAlD
Afatinib—DYRK1A—respiratory system—obesity	0.00598	0.0297	CbGeAlD
Afatinib—BLK—adrenal gland—obesity	0.00549	0.0272	CbGeAlD
Afatinib—IRAK1—islet of Langerhans—obesity	0.00492	0.0244	CbGeAlD
Afatinib—HIPK4—endocrine gland—obesity	0.00476	0.0236	CbGeAlD
Afatinib—ERBB2—cardiovascular system—obesity	0.00476	0.0236	CbGeAlD
Afatinib—ERBB4—cardiovascular system—obesity	0.00476	0.0236	CbGeAlD
Afatinib—PHKG2—adipose tissue—obesity	0.00466	0.0232	CbGeAlD
Afatinib—DYRK1A—cardiovascular system—obesity	0.00458	0.0227	CbGeAlD
Afatinib—ABL1—hindbrain—obesity	0.00426	0.0212	CbGeAlD
Afatinib—ERBB4—pituitary gland—obesity	0.00421	0.0209	CbGeAlD
Afatinib—ERBB2—adipose tissue—obesity	0.00419	0.0208	CbGeAlD
Afatinib—ERBB4—adipose tissue—obesity	0.00419	0.0208	CbGeAlD
Afatinib—PHKG2—adrenal gland—obesity	0.00418	0.0208	CbGeAlD
Afatinib—DYRK1A—adipose tissue—obesity	0.00404	0.02	CbGeAlD
Afatinib—ERBB2—digestive system—obesity	0.00395	0.0196	CbGeAlD
Afatinib—EPHA6—endocrine gland—obesity	0.00376	0.0187	CbGeAlD
Afatinib—ERBB2—adrenal gland—obesity	0.00376	0.0187	CbGeAlD
Afatinib—PHKG2—endocrine gland—obesity	0.00363	0.018	CbGeAlD
Afatinib—DYRK1A—adrenal gland—obesity	0.00362	0.018	CbGeAlD
Afatinib—EGFR—adipose tissue—obesity	0.00356	0.0177	CbGeAlD
Afatinib—PHKG2—liver—obesity	0.00327	0.0162	CbGeAlD
Afatinib—ERBB2—endocrine gland—obesity	0.00326	0.0162	CbGeAlD
Afatinib—ERBB4—endocrine gland—obesity	0.00326	0.0162	CbGeAlD
Afatinib—EGFR—adrenal gland—obesity	0.00319	0.0158	CbGeAlD
Afatinib—DYRK1A—endocrine gland—obesity	0.00314	0.0156	CbGeAlD
Afatinib—IRAK1—adipose tissue—obesity	0.00314	0.0156	CbGeAlD
Afatinib—LCK—adipose tissue—obesity	0.00306	0.0152	CbGeAlD
Afatinib—ERBB2—liver—obesity	0.00294	0.0146	CbGeAlD
Afatinib—DYRK1A—liver—obesity	0.00283	0.0141	CbGeAlD
Afatinib—IRAK1—adrenal gland—obesity	0.00281	0.014	CbGeAlD
Afatinib—ABL1—islet of Langerhans—obesity	0.00276	0.0137	CbGeAlD
Afatinib—LCK—adrenal gland—obesity	0.00274	0.0136	CbGeAlD
Afatinib—ABL1—respiratory system—obesity	0.0026	0.0129	CbGeAlD
Afatinib—EGFR—liver—obesity	0.00249	0.0124	CbGeAlD
Afatinib—Insomnia—Benzphetamine—obesity	0.0024	0.00774	CcSEcCtD
Afatinib—Cystitis noninfective—Sibutramine—obesity	0.0024	0.00772	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methamphetamine—obesity	0.00238	0.00766	CcSEcCtD
Afatinib—Cystitis—Sibutramine—obesity	0.00237	0.00763	CcSEcCtD
Afatinib—Constipation—Methamphetamine—obesity	0.00236	0.00759	CcSEcCtD
Afatinib—Dyspepsia—Benzphetamine—obesity	0.00234	0.00753	CcSEcCtD
Afatinib—Decreased appetite—Benzphetamine—obesity	0.00231	0.00744	CcSEcCtD
Afatinib—Gastrointestinal disorder—Benzphetamine—obesity	0.00229	0.00739	CcSEcCtD
Afatinib—Dry eye—Sibutramine—obesity	0.00227	0.0073	CcSEcCtD
Afatinib—Mouth ulceration—Sibutramine—obesity	0.00222	0.00715	CcSEcCtD
Afatinib—Bladder pain—Sibutramine—obesity	0.00222	0.00715	CcSEcCtD
Afatinib—IRAK1—liver—obesity	0.0022	0.0109	CbGeAlD
Afatinib—Insomnia—Phendimetrazine—obesity	0.00219	0.00705	CcSEcCtD
Afatinib—ABL1—adrenal cortex—obesity	0.00218	0.0108	CbGeAlD
Afatinib—LCK—liver—obesity	0.00215	0.0107	CbGeAlD
Afatinib—Alopecia—Diethylpropion—obesity	0.00214	0.0069	CcSEcCtD
Afatinib—Sepsis—Sibutramine—obesity	0.00213	0.00686	CcSEcCtD
Afatinib—Decreased appetite—Phendimetrazine—obesity	0.0021	0.00678	CcSEcCtD
Afatinib—Cystitis noninfective—Bupropion—obesity	0.00209	0.00673	CcSEcCtD
Afatinib—Constipation—Phendimetrazine—obesity	0.00207	0.00667	CcSEcCtD
Afatinib—Cystitis—Bupropion—obesity	0.00206	0.00665	CcSEcCtD
Afatinib—Alopecia—Cimetidine—obesity	0.00204	0.00656	CcSEcCtD
Afatinib—ABL1—cardiovascular system—obesity	0.00199	0.00989	CbGeAlD
Afatinib—Dry eye—Bupropion—obesity	0.00198	0.00636	CcSEcCtD
Afatinib—Bladder pain—Bupropion—obesity	0.00193	0.00623	CcSEcCtD
Afatinib—Mouth ulceration—Bupropion—obesity	0.00193	0.00623	CcSEcCtD
Afatinib—Diarrhoea—Methamphetamine—obesity	0.00188	0.00607	CcSEcCtD
Afatinib—Renal impairment—Sibutramine—obesity	0.00187	0.00603	CcSEcCtD
Afatinib—Insomnia—Phenylpropanolamine—obesity	0.00187	0.00603	CcSEcCtD
Afatinib—Dyspnoea—Phenylpropanolamine—obesity	0.00184	0.00594	CcSEcCtD
Afatinib—Dizziness—Methamphetamine—obesity	0.00182	0.00587	CcSEcCtD
Afatinib—Diarrhoea—Benzphetamine—obesity	0.00182	0.00585	CcSEcCtD
Afatinib—Insomnia—Phentermine—obesity	0.00179	0.00577	CcSEcCtD
Afatinib—Constipation—Phenylpropanolamine—obesity	0.00177	0.0057	CcSEcCtD
Afatinib—ABL1—pituitary gland—obesity	0.00176	0.00876	CbGeAlD
Afatinib—ABL1—adipose tissue—obesity	0.00176	0.00872	CbGeAlD
Afatinib—Dizziness—Benzphetamine—obesity	0.00176	0.00566	CcSEcCtD
Afatinib—Dyspepsia—Phentermine—obesity	0.00174	0.00561	CcSEcCtD
Afatinib—Headache—Methamphetamine—obesity	0.00173	0.00556	CcSEcCtD
Afatinib—Gastrointestinal disorder—Phentermine—obesity	0.00171	0.0055	CcSEcCtD
Afatinib—Fatigue—Phentermine—obesity	0.00171	0.0055	CcSEcCtD
Afatinib—Constipation—Phentermine—obesity	0.00169	0.00545	CcSEcCtD
Afatinib—Dry skin—Orlistat—obesity	0.00169	0.00543	CcSEcCtD
Afatinib—Rhinorrhoea—Topiramate—obesity	0.00168	0.00542	CcSEcCtD
Afatinib—Hypokalaemia—Orlistat—obesity	0.00167	0.00539	CcSEcCtD
Afatinib—Headache—Benzphetamine—obesity	0.00166	0.00536	CcSEcCtD
Afatinib—Diarrhoea—Phendimetrazine—obesity	0.00166	0.00534	CcSEcCtD
Afatinib—Dehydration—Sibutramine—obesity	0.00166	0.00534	CcSEcCtD
Afatinib—ABL1—digestive system—obesity	0.00165	0.00821	CbGeAlD
Afatinib—Dry skin—Sibutramine—obesity	0.00163	0.00526	CcSEcCtD
Afatinib—Hypokalaemia—Sibutramine—obesity	0.00162	0.00522	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Sibutramine—obesity	0.0016	0.00517	CcSEcCtD
Afatinib—Dizziness—Phendimetrazine—obesity	0.0016	0.00516	CcSEcCtD
Afatinib—Nausea—Benzphetamine—obesity	0.00158	0.00508	CcSEcCtD
Afatinib—ABL1—adrenal gland—obesity	0.00158	0.00783	CbGeAlD
Afatinib—Alanine aminotransferase increased—Sibutramine—obesity	0.00157	0.00506	CcSEcCtD
Afatinib—Insomnia—Diethylpropion—obesity	0.00156	0.00502	CcSEcCtD
Afatinib—Dyspnoea—Diethylpropion—obesity	0.00153	0.00494	CcSEcCtD
Afatinib—Headache—Phendimetrazine—obesity	0.00152	0.00489	CcSEcCtD
Afatinib—Dyspepsia—Diethylpropion—obesity	0.00152	0.00488	CcSEcCtD
Afatinib—Gastrointestinal disorder—Diethylpropion—obesity	0.00149	0.00479	CcSEcCtD
Afatinib—Upper respiratory tract infection—Orlistat—obesity	0.00148	0.00476	CcSEcCtD
Afatinib—Constipation—Diethylpropion—obesity	0.00147	0.00474	CcSEcCtD
Afatinib—Dehydration—Bupropion—obesity	0.00144	0.00465	CcSEcCtD
Afatinib—Nausea—Phendimetrazine—obesity	0.00144	0.00463	CcSEcCtD
Afatinib—Dry skin—Bupropion—obesity	0.00142	0.00458	CcSEcCtD
Afatinib—Asthenia—Phentermine—obesity	0.00142	0.00457	CcSEcCtD
Afatinib—Infestation NOS—Orlistat—obesity	0.00142	0.00457	CcSEcCtD
Afatinib—Infestation—Orlistat—obesity	0.00142	0.00457	CcSEcCtD
Afatinib—Fatigue—Cimetidine—obesity	0.00141	0.00455	CcSEcCtD
Afatinib—Constipation—Cimetidine—obesity	0.0014	0.00451	CcSEcCtD
Afatinib—Renal failure—Orlistat—obesity	0.00139	0.00449	CcSEcCtD
Afatinib—Nasopharyngitis—Bupropion—obesity	0.00139	0.00447	CcSEcCtD
Afatinib—Pneumonia—Sibutramine—obesity	0.00138	0.00445	CcSEcCtD
Afatinib—Urinary tract infection—Orlistat—obesity	0.00138	0.00444	CcSEcCtD
Afatinib—ABCG2—adrenal cortex—obesity	0.00138	0.00684	CbGeAlD
Afatinib—Dizziness—Phenylpropanolamine—obesity	0.00137	0.00441	CcSEcCtD
Afatinib—ABL1—endocrine gland—obesity	0.00137	0.00679	CbGeAlD
Afatinib—Diarrhoea—Phentermine—obesity	0.00135	0.00436	CcSEcCtD
Afatinib—Renal failure—Sibutramine—obesity	0.00135	0.00435	CcSEcCtD
Afatinib—Hepatobiliary disease—Orlistat—obesity	0.00134	0.00432	CcSEcCtD
Afatinib—Stomatitis—Sibutramine—obesity	0.00134	0.00431	CcSEcCtD
Afatinib—Conjunctivitis—Sibutramine—obesity	0.00133	0.0043	CcSEcCtD
Afatinib—Urinary tract infection—Sibutramine—obesity	0.00133	0.0043	CcSEcCtD
Afatinib—Cystitis noninfective—Topiramate—obesity	0.00133	0.00429	CcSEcCtD
Afatinib—Cystitis—Topiramate—obesity	0.00132	0.00424	CcSEcCtD
Afatinib—Vomiting—Phenylpropanolamine—obesity	0.00131	0.00424	CcSEcCtD
Afatinib—Dizziness—Phentermine—obesity	0.00131	0.00422	CcSEcCtD
Afatinib—Rash—Phenylpropanolamine—obesity	0.0013	0.0042	CcSEcCtD
Afatinib—Dermatitis—Phenylpropanolamine—obesity	0.0013	0.0042	CcSEcCtD
Afatinib—Body temperature increased—Cimetidine—obesity	0.00129	0.00417	CcSEcCtD
Afatinib—Epistaxis—Sibutramine—obesity	0.00129	0.00417	CcSEcCtD
Afatinib—Dry eye—Topiramate—obesity	0.00126	0.00405	CcSEcCtD
Afatinib—Vomiting—Phentermine—obesity	0.00126	0.00405	CcSEcCtD
Afatinib—Urinary tract disorder—Orlistat—obesity	0.00126	0.00405	CcSEcCtD
Afatinib—Urethral disorder—Orlistat—obesity	0.00125	0.00402	CcSEcCtD
Afatinib—Rash—Phentermine—obesity	0.00125	0.00402	CcSEcCtD
Afatinib—Upper respiratory tract infection—Bupropion—obesity	0.00125	0.00402	CcSEcCtD
Afatinib—Dermatitis—Phentermine—obesity	0.00125	0.00402	CcSEcCtD
Afatinib—Headache—Phentermine—obesity	0.00124	0.00399	CcSEcCtD
Afatinib—ABL1—liver—obesity	0.00123	0.00612	CbGeAlD
Afatinib—Bladder pain—Topiramate—obesity	0.00123	0.00397	CcSEcCtD
Afatinib—Mouth ulceration—Topiramate—obesity	0.00123	0.00397	CcSEcCtD
Afatinib—Nausea—Phenylpropanolamine—obesity	0.00123	0.00396	CcSEcCtD
Afatinib—Weight decreased—Bupropion—obesity	0.00121	0.00391	CcSEcCtD
Afatinib—Pneumonia—Bupropion—obesity	0.0012	0.00388	CcSEcCtD
Afatinib—Infestation—Bupropion—obesity	0.0012	0.00385	CcSEcCtD
Afatinib—Infestation NOS—Bupropion—obesity	0.0012	0.00385	CcSEcCtD
Afatinib—Diarrhoea—Diethylpropion—obesity	0.00118	0.00379	CcSEcCtD
Afatinib—Nausea—Phentermine—obesity	0.00118	0.00379	CcSEcCtD
Afatinib—Asthenia—Cimetidine—obesity	0.00118	0.00379	CcSEcCtD
Afatinib—Stomatitis—Bupropion—obesity	0.00117	0.00376	CcSEcCtD
Afatinib—Conjunctivitis—Bupropion—obesity	0.00116	0.00375	CcSEcCtD
Afatinib—Urinary tract infection—Bupropion—obesity	0.00116	0.00375	CcSEcCtD
Afatinib—Eye disorder—Sibutramine—obesity	0.00115	0.00371	CcSEcCtD
Afatinib—Mediastinal disorder—Orlistat—obesity	0.00115	0.0037	CcSEcCtD
Afatinib—Dizziness—Diethylpropion—obesity	0.00114	0.00367	CcSEcCtD
Afatinib—Epistaxis—Bupropion—obesity	0.00113	0.00364	CcSEcCtD
Afatinib—Alopecia—Orlistat—obesity	0.00112	0.00362	CcSEcCtD
Afatinib—Diarrhoea—Cimetidine—obesity	0.00112	0.00361	CcSEcCtD
Afatinib—Mental disorder—Orlistat—obesity	0.00112	0.00359	CcSEcCtD
Afatinib—ABCG2—pituitary gland—obesity	0.00111	0.00552	CbGeAlD
Afatinib—ABCG2—adipose tissue—obesity	0.00111	0.0055	CbGeAlD
Afatinib—Malnutrition—Orlistat—obesity	0.00111	0.00357	CcSEcCtD
Afatinib—Vomiting—Diethylpropion—obesity	0.00109	0.00353	CcSEcCtD
Afatinib—Alopecia—Sibutramine—obesity	0.00109	0.00351	CcSEcCtD
Afatinib—Rash—Diethylpropion—obesity	0.00109	0.0035	CcSEcCtD
Afatinib—Dysgeusia—Orlistat—obesity	0.00109	0.0035	CcSEcCtD
Afatinib—Dermatitis—Diethylpropion—obesity	0.00108	0.00349	CcSEcCtD
Afatinib—Dizziness—Cimetidine—obesity	0.00108	0.00349	CcSEcCtD
Afatinib—Headache—Diethylpropion—obesity	0.00108	0.00347	CcSEcCtD
Afatinib—Malnutrition—Sibutramine—obesity	0.00107	0.00345	CcSEcCtD
Afatinib—Back pain—Orlistat—obesity	0.00107	0.00345	CcSEcCtD
Afatinib—Muscle spasms—Orlistat—obesity	0.00107	0.00343	CcSEcCtD
Afatinib—Urinary tract disorder—Bupropion—obesity	0.00106	0.00342	CcSEcCtD
Afatinib—Connective tissue disorder—Bupropion—obesity	0.00106	0.0034	CcSEcCtD
Afatinib—Urethral disorder—Bupropion—obesity	0.00105	0.00339	CcSEcCtD
Afatinib—Dysgeusia—Sibutramine—obesity	0.00105	0.00338	CcSEcCtD
Afatinib—Vomiting—Cimetidine—obesity	0.00104	0.00336	CcSEcCtD
Afatinib—Back pain—Sibutramine—obesity	0.00104	0.00334	CcSEcCtD
Afatinib—Rash—Cimetidine—obesity	0.00103	0.00333	CcSEcCtD
Afatinib—Dermatitis—Cimetidine—obesity	0.00103	0.00332	CcSEcCtD
Afatinib—Muscle spasms—Sibutramine—obesity	0.00103	0.00332	CcSEcCtD
Afatinib—Headache—Cimetidine—obesity	0.00103	0.00331	CcSEcCtD
Afatinib—Nausea—Diethylpropion—obesity	0.00102	0.00329	CcSEcCtD
Afatinib—Eye disorder—Bupropion—obesity	0.001	0.00323	CcSEcCtD
Afatinib—ABCG2—adrenal gland—obesity	0.000994	0.00493	CbGeAlD
Afatinib—Nausea—Cimetidine—obesity	0.000973	0.00313	CcSEcCtD
Afatinib—Mediastinal disorder—Bupropion—obesity	0.000968	0.00312	CcSEcCtD
Afatinib—Cough—Orlistat—obesity	0.000967	0.00312	CcSEcCtD
Afatinib—Alopecia—Bupropion—obesity	0.000949	0.00306	CcSEcCtD
Afatinib—Mental disorder—Bupropion—obesity	0.000941	0.00303	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000937	0.00302	CcSEcCtD
Afatinib—Cough—Sibutramine—obesity	0.000936	0.00301	CcSEcCtD
Afatinib—Malnutrition—Bupropion—obesity	0.000935	0.00301	CcSEcCtD
Afatinib—Dehydration—Topiramate—obesity	0.00092	0.00296	CcSEcCtD
Afatinib—Dysgeusia—Bupropion—obesity	0.000915	0.00295	CcSEcCtD
Afatinib—Back pain—Bupropion—obesity	0.000904	0.00291	CcSEcCtD
Afatinib—Hypokalaemia—Topiramate—obesity	0.0009	0.0029	CcSEcCtD
Afatinib—Muscle spasms—Bupropion—obesity	0.000899	0.0029	CcSEcCtD
Afatinib—Infection—Orlistat—obesity	0.000898	0.00289	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Topiramate—obesity	0.000891	0.00287	CcSEcCtD
Afatinib—Nervous system disorder—Orlistat—obesity	0.000887	0.00286	CcSEcCtD
Afatinib—Nasopharyngitis—Topiramate—obesity	0.000884	0.00285	CcSEcCtD
Afatinib—Skin disorder—Orlistat—obesity	0.000878	0.00283	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Topiramate—obesity	0.000872	0.00281	CcSEcCtD
Afatinib—Infection—Sibutramine—obesity	0.000869	0.0028	CcSEcCtD
Afatinib—ABCB1—islet of Langerhans—obesity	0.000857	0.00425	CbGeAlD
Afatinib—Skin disorder—Sibutramine—obesity	0.00085	0.00274	CcSEcCtD
Afatinib—Insomnia—Orlistat—obesity	0.000818	0.00264	CcSEcCtD
Afatinib—Cough—Bupropion—obesity	0.000816	0.00263	CcSEcCtD
Afatinib—ABCB1—respiratory system—obesity	0.000809	0.00402	CbGeAlD
Afatinib—Dyspepsia—Orlistat—obesity	0.000796	0.00256	CcSEcCtD
Afatinib—Upper respiratory tract infection—Topiramate—obesity	0.000794	0.00256	CcSEcCtD
Afatinib—Insomnia—Sibutramine—obesity	0.000792	0.00255	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.00079	0.00255	CcSEcCtD
Afatinib—Decreased appetite—Orlistat—obesity	0.000786	0.00253	CcSEcCtD
Afatinib—Gastrointestinal disorder—Orlistat—obesity	0.000781	0.00252	CcSEcCtD
Afatinib—Dyspnoea—Sibutramine—obesity	0.00078	0.00251	CcSEcCtD
Afatinib—Fatigue—Orlistat—obesity	0.00078	0.00251	CcSEcCtD
Afatinib—ABCG2—liver—obesity	0.000777	0.00386	CbGeAlD
Afatinib—Weight decreased—Topiramate—obesity	0.000773	0.00249	CcSEcCtD
Afatinib—Dyspepsia—Sibutramine—obesity	0.00077	0.00248	CcSEcCtD
Afatinib—Pneumonia—Topiramate—obesity	0.000767	0.00247	CcSEcCtD
Afatinib—Infestation NOS—Topiramate—obesity	0.000762	0.00246	CcSEcCtD
Afatinib—Infestation—Topiramate—obesity	0.000762	0.00246	CcSEcCtD
Afatinib—Decreased appetite—Sibutramine—obesity	0.000761	0.00245	CcSEcCtD
Afatinib—Infection—Bupropion—obesity	0.000758	0.00244	CcSEcCtD
Afatinib—Gastrointestinal disorder—Sibutramine—obesity	0.000756	0.00243	CcSEcCtD
Afatinib—Renal failure—Topiramate—obesity	0.000749	0.00241	CcSEcCtD
Afatinib—Constipation—Sibutramine—obesity	0.000748	0.00241	CcSEcCtD
Afatinib—Nervous system disorder—Bupropion—obesity	0.000748	0.00241	CcSEcCtD
Afatinib—Stomatitis—Topiramate—obesity	0.000743	0.00239	CcSEcCtD
Afatinib—Skin disorder—Bupropion—obesity	0.000741	0.00239	CcSEcCtD
Afatinib—Conjunctivitis—Topiramate—obesity	0.000741	0.00239	CcSEcCtD
Afatinib—Urinary tract infection—Topiramate—obesity	0.000741	0.00239	CcSEcCtD
Afatinib—Epistaxis—Topiramate—obesity	0.000719	0.00232	CcSEcCtD
Afatinib—Body temperature increased—Orlistat—obesity	0.000715	0.0023	CcSEcCtD
Afatinib—Body temperature increased—Sibutramine—obesity	0.000692	0.00223	CcSEcCtD
Afatinib—Insomnia—Bupropion—obesity	0.00069	0.00222	CcSEcCtD
Afatinib—Dyspnoea—Bupropion—obesity	0.00068	0.00219	CcSEcCtD
Afatinib—ABCB1—adrenal cortex—obesity	0.000679	0.00337	CbGeAlD
Afatinib—Urinary tract disorder—Topiramate—obesity	0.000676	0.00218	CcSEcCtD
Afatinib—Connective tissue disorder—Topiramate—obesity	0.000672	0.00217	CcSEcCtD
Afatinib—Dyspepsia—Bupropion—obesity	0.000672	0.00216	CcSEcCtD
Afatinib—Urethral disorder—Topiramate—obesity	0.000671	0.00216	CcSEcCtD
Afatinib—Decreased appetite—Bupropion—obesity	0.000663	0.00214	CcSEcCtD
Afatinib—Gastrointestinal disorder—Bupropion—obesity	0.000659	0.00212	CcSEcCtD
Afatinib—Fatigue—Bupropion—obesity	0.000658	0.00212	CcSEcCtD
Afatinib—Constipation—Bupropion—obesity	0.000652	0.0021	CcSEcCtD
Afatinib—Asthenia—Orlistat—obesity	0.000649	0.00209	CcSEcCtD
Afatinib—Pruritus—Orlistat—obesity	0.00064	0.00206	CcSEcCtD
Afatinib—Eye disorder—Topiramate—obesity	0.000639	0.00206	CcSEcCtD
Afatinib—Asthenia—Sibutramine—obesity	0.000628	0.00202	CcSEcCtD
Afatinib—ABCB1—cardiovascular system—obesity	0.00062	0.00308	CbGeAlD
Afatinib—Pruritus—Sibutramine—obesity	0.000619	0.00199	CcSEcCtD
Afatinib—Diarrhoea—Orlistat—obesity	0.000619	0.00199	CcSEcCtD
Afatinib—Mediastinal disorder—Topiramate—obesity	0.000617	0.00199	CcSEcCtD
Afatinib—Alopecia—Topiramate—obesity	0.000605	0.00195	CcSEcCtD
Afatinib—Body temperature increased—Bupropion—obesity	0.000603	0.00194	CcSEcCtD
Afatinib—Mental disorder—Topiramate—obesity	0.000599	0.00193	CcSEcCtD
Afatinib—Diarrhoea—Sibutramine—obesity	0.000599	0.00193	CcSEcCtD
Afatinib—Dizziness—Orlistat—obesity	0.000598	0.00193	CcSEcCtD
Afatinib—Malnutrition—Topiramate—obesity	0.000596	0.00192	CcSEcCtD
Afatinib—Dysgeusia—Topiramate—obesity	0.000583	0.00188	CcSEcCtD
Afatinib—Dizziness—Sibutramine—obesity	0.000579	0.00186	CcSEcCtD
Afatinib—Back pain—Topiramate—obesity	0.000576	0.00186	CcSEcCtD
Afatinib—Vomiting—Orlistat—obesity	0.000575	0.00185	CcSEcCtD
Afatinib—Muscle spasms—Topiramate—obesity	0.000573	0.00184	CcSEcCtD
Afatinib—Rash—Orlistat—obesity	0.00057	0.00184	CcSEcCtD
Afatinib—Dermatitis—Orlistat—obesity	0.00057	0.00184	CcSEcCtD
Afatinib—Headache—Orlistat—obesity	0.000567	0.00183	CcSEcCtD
Afatinib—Vomiting—Sibutramine—obesity	0.000556	0.00179	CcSEcCtD
Afatinib—Rash—Sibutramine—obesity	0.000552	0.00178	CcSEcCtD
Afatinib—Dermatitis—Sibutramine—obesity	0.000551	0.00178	CcSEcCtD
Afatinib—ABCB1—pituitary gland—obesity	0.000549	0.00272	CbGeAlD
Afatinib—Headache—Sibutramine—obesity	0.000548	0.00177	CcSEcCtD
Afatinib—Asthenia—Bupropion—obesity	0.000547	0.00176	CcSEcCtD
Afatinib—ABCB1—adipose tissue—obesity	0.000547	0.00271	CbGeAlD
Afatinib—Pruritus—Bupropion—obesity	0.00054	0.00174	CcSEcCtD
Afatinib—Nausea—Orlistat—obesity	0.000537	0.00173	CcSEcCtD
Afatinib—Diarrhoea—Bupropion—obesity	0.000522	0.00168	CcSEcCtD
Afatinib—Nausea—Sibutramine—obesity	0.00052	0.00167	CcSEcCtD
Afatinib—Cough—Topiramate—obesity	0.00052	0.00167	CcSEcCtD
Afatinib—ABCB1—digestive system—obesity	0.000514	0.00255	CbGeAlD
Afatinib—Dizziness—Bupropion—obesity	0.000505	0.00163	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000504	0.00162	CcSEcCtD
Afatinib—ABCB1—adrenal gland—obesity	0.00049	0.00243	CbGeAlD
Afatinib—Vomiting—Bupropion—obesity	0.000485	0.00156	CcSEcCtD
Afatinib—Infection—Topiramate—obesity	0.000483	0.00156	CcSEcCtD
Afatinib—Rash—Bupropion—obesity	0.000481	0.00155	CcSEcCtD
Afatinib—Dermatitis—Bupropion—obesity	0.000481	0.00155	CcSEcCtD
Afatinib—Headache—Bupropion—obesity	0.000478	0.00154	CcSEcCtD
Afatinib—Nervous system disorder—Topiramate—obesity	0.000477	0.00154	CcSEcCtD
Afatinib—Skin disorder—Topiramate—obesity	0.000472	0.00152	CcSEcCtD
Afatinib—Nausea—Bupropion—obesity	0.000453	0.00146	CcSEcCtD
Afatinib—Insomnia—Topiramate—obesity	0.00044	0.00142	CcSEcCtD
Afatinib—Dyspnoea—Topiramate—obesity	0.000433	0.0014	CcSEcCtD
Afatinib—Dyspepsia—Topiramate—obesity	0.000428	0.00138	CcSEcCtD
Afatinib—ABCB1—endocrine gland—obesity	0.000425	0.00211	CbGeAlD
Afatinib—Decreased appetite—Topiramate—obesity	0.000423	0.00136	CcSEcCtD
Afatinib—Gastrointestinal disorder—Topiramate—obesity	0.00042	0.00135	CcSEcCtD
Afatinib—Fatigue—Topiramate—obesity	0.000419	0.00135	CcSEcCtD
Afatinib—Constipation—Topiramate—obesity	0.000416	0.00134	CcSEcCtD
Afatinib—Body temperature increased—Topiramate—obesity	0.000384	0.00124	CcSEcCtD
Afatinib—ABCB1—liver—obesity	0.000383	0.0019	CbGeAlD
Afatinib—Asthenia—Topiramate—obesity	0.000349	0.00112	CcSEcCtD
Afatinib—Pruritus—Topiramate—obesity	0.000344	0.00111	CcSEcCtD
Afatinib—Diarrhoea—Topiramate—obesity	0.000333	0.00107	CcSEcCtD
Afatinib—Dizziness—Topiramate—obesity	0.000321	0.00104	CcSEcCtD
Afatinib—Vomiting—Topiramate—obesity	0.000309	0.000996	CcSEcCtD
Afatinib—Rash—Topiramate—obesity	0.000306	0.000987	CcSEcCtD
Afatinib—Dermatitis—Topiramate—obesity	0.000306	0.000987	CcSEcCtD
Afatinib—Headache—Topiramate—obesity	0.000305	0.000981	CcSEcCtD
Afatinib—Nausea—Topiramate—obesity	0.000289	0.00093	CcSEcCtD
Afatinib—LCK—Signaling Pathways—LPL—obesity	1.04e-05	2.12e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TYK2—obesity	1.03e-05	2.11e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FOXO1—obesity	1.03e-05	2.11e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AGT—obesity	1.03e-05	2.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RPS6KB1—obesity	1.03e-05	2.1e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CETP—obesity	1.03e-05	2.1e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TYK2—obesity	1.03e-05	2.1e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT2—obesity	1.02e-05	2.1e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CD—obesity	1.02e-05	2.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RHOA—obesity	1.02e-05	2.09e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—obesity	1.02e-05	2.09e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SDC1—obesity	1.02e-05	2.08e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—obesity	1.01e-05	2.07e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SERPINE1—obesity	1.01e-05	2.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3R1—obesity	1.01e-05	2.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOS3—obesity	1.01e-05	2.07e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—obesity	1.01e-05	2.07e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—obesity	1.01e-05	2.06e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3R1—obesity	1.01e-05	2.06e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—obesity	1.01e-05	2.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2—obesity	1.01e-05	2.06e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKR1C3—obesity	9.99e-06	2.05e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAV1—obesity	9.97e-06	2.04e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—obesity	9.97e-06	2.04e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—obesity	9.97e-06	2.04e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOA1—obesity	9.95e-06	2.04e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—obesity	9.94e-06	2.04e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—obesity	9.93e-06	2.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PRKCD—obesity	9.91e-06	2.03e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CD—obesity	9.84e-06	2.02e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SCARB1—obesity	9.83e-06	2.01e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TYK2—obesity	9.83e-06	2.01e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—obesity	9.82e-06	2.01e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—obesity	9.79e-06	2.01e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—obesity	9.79e-06	2e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—RHOA—obesity	9.75e-06	2e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SERPINE1—obesity	9.74e-06	1.99e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—obesity	9.73e-06	1.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HTR2A—obesity	9.7e-06	1.99e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2—obesity	9.69e-06	1.99e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—obesity	9.69e-06	1.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—C3—obesity	9.68e-06	1.98e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—obesity	9.65e-06	1.98e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3R1—obesity	9.65e-06	1.98e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS3—obesity	9.65e-06	1.98e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MTOR—obesity	9.64e-06	1.98e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CB—obesity	9.64e-06	1.98e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—obesity	9.6e-06	1.97e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PRKCD—obesity	9.55e-06	1.96e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SREBF1—obesity	9.54e-06	1.95e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK8—obesity	9.54e-06	1.95e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TYK2—obesity	9.47e-06	1.94e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—obesity	9.41e-06	1.93e-05	CbGpPWpGaD
Afatinib—LCK—Disease—RHOA—obesity	9.39e-06	1.92e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HTR2A—obesity	9.35e-06	1.91e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—obesity	9.34e-06	1.91e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—obesity	9.34e-06	1.91e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—C3—obesity	9.33e-06	1.91e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CB—obesity	9.32e-06	1.91e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MTOR—obesity	9.32e-06	1.91e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3R1—obesity	9.3e-06	1.9e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS3—obesity	9.3e-06	1.9e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MTOR—obesity	9.29e-06	1.9e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CB—obesity	9.29e-06	1.9e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GOT2—obesity	9.28e-06	1.9e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—obesity	9.26e-06	1.9e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—obesity	9.24e-06	1.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS2—obesity	9.21e-06	1.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AGT—obesity	9.2e-06	1.89e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—obesity	9.17e-06	1.88e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—obesity	9.12e-06	1.87e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—obesity	9.1e-06	1.86e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—obesity	9.1e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—obesity	9.08e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—FASN—obesity	9.08e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—BCHE—obesity	9.05e-06	1.85e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—obesity	9.03e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LEP—obesity	9.02e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—obesity	9.02e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—obesity	8.94e-06	1.83e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CAV1—obesity	8.93e-06	1.83e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOA1—obesity	8.91e-06	1.83e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—obesity	8.9e-06	1.82e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTOR—obesity	8.9e-06	1.82e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—obesity	8.89e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS2—obesity	8.88e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AGT—obesity	8.87e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—obesity	8.83e-06	1.81e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—obesity	8.82e-06	1.81e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—obesity	8.79e-06	1.8e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—obesity	8.77e-06	1.8e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2E1—obesity	8.73e-06	1.79e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—obesity	8.72e-06	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LEP—obesity	8.69e-06	1.78e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—obesity	8.69e-06	1.78e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—POMC—obesity	8.65e-06	1.77e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NQO1—obesity	8.63e-06	1.77e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—obesity	8.61e-06	1.76e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CAV1—obesity	8.61e-06	1.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—obesity	8.61e-06	1.76e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—INS—obesity	8.6e-06	1.76e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOA1—obesity	8.59e-06	1.76e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—obesity	8.58e-06	1.76e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTOR—obesity	8.58e-06	1.76e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—obesity	8.57e-06	1.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—F2—obesity	8.5e-06	1.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PRKCB—obesity	8.5e-06	1.74e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—obesity	8.5e-06	1.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BAD—obesity	8.4e-06	1.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—obesity	8.3e-06	1.7e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GCG—obesity	8.27e-06	1.7e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A4—obesity	8.27e-06	1.7e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—obesity	8.25e-06	1.69e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PRKCB—obesity	8.19e-06	1.68e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—F2—obesity	8.19e-06	1.68e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYCS—obesity	8.17e-06	1.67e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK8—obesity	8.15e-06	1.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—obesity	8.14e-06	1.67e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—obesity	8.1e-06	1.66e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BAD—obesity	8.1e-06	1.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS1—obesity	8.04e-06	1.65e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GOT1—obesity	8.01e-06	1.64e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GGT1—obesity	8.01e-06	1.64e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—obesity	7.99e-06	1.64e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—obesity	7.95e-06	1.63e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—obesity	7.92e-06	1.62e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NCOA1—obesity	7.89e-06	1.62e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—obesity	7.88e-06	1.62e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK8—obesity	7.88e-06	1.61e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—obesity	7.86e-06	1.61e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK8—obesity	7.86e-06	1.61e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—obesity	7.84e-06	1.61e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—obesity	7.79e-06	1.59e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP19A1—obesity	7.78e-06	1.59e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—STK11—obesity	7.78e-06	1.59e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS1—obesity	7.75e-06	1.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—POMC—obesity	7.75e-06	1.59e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—obesity	7.74e-06	1.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—INS—obesity	7.7e-06	1.58e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—obesity	7.63e-06	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—obesity	7.58e-06	1.55e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3R1—obesity	7.54e-06	1.54e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—obesity	7.54e-06	1.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—POMC—obesity	7.46e-06	1.53e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—obesity	7.45e-06	1.53e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—obesity	7.45e-06	1.53e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT2—obesity	7.45e-06	1.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—INS—obesity	7.42e-06	1.52e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—obesity	7.3e-06	1.5e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—COMT—obesity	7.23e-06	1.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—obesity	7.21e-06	1.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—obesity	7.18e-06	1.47e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—obesity	7.18e-06	1.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—obesity	7.18e-06	1.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT2—obesity	7.17e-06	1.47e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—obesity	7.15e-06	1.47e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARGC1A—obesity	7.13e-06	1.46e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GNB3—obesity	7.13e-06	1.46e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—obesity	7.1e-06	1.45e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SERPINE1—obesity	7.08e-06	1.45e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—obesity	6.96e-06	1.43e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—obesity	6.96e-06	1.43e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GNAS—obesity	6.94e-06	1.42e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—obesity	6.9e-06	1.41e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—obesity	6.89e-06	1.41e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TYK2—obesity	6.88e-06	1.41e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—obesity	6.88e-06	1.41e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—obesity	6.88e-06	1.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—obesity	6.86e-06	1.4e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RHOA—obesity	6.83e-06	1.4e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SERPINE1—obesity	6.82e-06	1.4e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOB—obesity	6.8e-06	1.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3R1—obesity	6.75e-06	1.38e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—obesity	6.75e-06	1.38e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—obesity	6.7e-06	1.37e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—obesity	6.68e-06	1.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TYK2—obesity	6.63e-06	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—obesity	6.63e-06	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RHOA—obesity	6.58e-06	1.35e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3R1—obesity	6.51e-06	1.33e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—obesity	6.51e-06	1.33e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—LPL—obesity	6.49e-06	1.33e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—obesity	6.43e-06	1.32e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—obesity	6.42e-06	1.32e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—obesity	6.39e-06	1.31e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—obesity	6.38e-06	1.31e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—obesity	6.33e-06	1.3e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—obesity	6.33e-06	1.3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—obesity	6.24e-06	1.28e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MTOR—obesity	6.24e-06	1.28e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CD36—obesity	6.17e-06	1.26e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—obesity	6.16e-06	1.26e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—obesity	6.15e-06	1.26e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—obesity	6.09e-06	1.25e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MTOR—obesity	6.01e-06	1.23e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—obesity	6.01e-06	1.23e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—obesity	5.88e-06	1.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—obesity	5.85e-06	1.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARA—obesity	5.74e-06	1.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—obesity	5.7e-06	1.17e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—obesity	5.68e-06	1.16e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—obesity	5.67e-06	1.16e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—obesity	5.62e-06	1.15e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AGT—obesity	5.55e-06	1.14e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—obesity	5.44e-06	1.11e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—obesity	5.43e-06	1.11e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—obesity	5.42e-06	1.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAV1—obesity	5.39e-06	1.1e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOA1—obesity	5.38e-06	1.1e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK8—obesity	5.27e-06	1.08e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—obesity	5.26e-06	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—obesity	5.23e-06	1.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—obesity	5.22e-06	1.07e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—obesity	5.21e-06	1.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK8—obesity	5.08e-06	1.04e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—obesity	5.03e-06	1.03e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—obesity	5.02e-06	1.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—obesity	4.91e-06	1.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—obesity	4.82e-06	9.87e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—obesity	4.81e-06	9.85e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—obesity	4.8e-06	9.84e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—obesity	4.74e-06	9.71e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—POMC—obesity	4.68e-06	9.58e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—INS—obesity	4.65e-06	9.52e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—obesity	4.64e-06	9.51e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—obesity	4.64e-06	9.51e-06	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—obesity	4.63e-06	9.49e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—obesity	4.63e-06	9.48e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—obesity	4.48e-06	9.17e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—obesity	4.47e-06	9.15e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—obesity	4.43e-06	9.08e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—obesity	4.32e-06	8.85e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—obesity	4.31e-06	8.84e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—obesity	4.3e-06	8.82e-06	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—obesity	4.27e-06	8.75e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—obesity	4.26e-06	8.73e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—obesity	4.24e-06	8.69e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—obesity	4.08e-06	8.35e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3R1—obesity	4.08e-06	8.35e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—obesity	3.8e-06	7.79e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—obesity	3.76e-06	7.71e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—obesity	3.73e-06	7.64e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—obesity	3.66e-06	7.5e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—obesity	3.47e-06	7.1e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—obesity	3.37e-06	6.89e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—obesity	3.24e-06	6.64e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—obesity	3.11e-06	6.36e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—obesity	2.99e-06	6.13e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—obesity	2.29e-06	4.7e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—obesity	1.87e-06	3.84e-06	CbGpPWpGaD
